Zerbaxa 1 g/0.5 g powder for concentrate for solution for infusion

DRUG2 trials

Sponsors

Merck Sharp & Dohme LLC, Fundacion Publica Andaluza Para La Gestion De La Investigacion En Salud De Sevilla

Conditions

Bacteriemia producida por P. aeruginosa.Nosocomial infectionPneumonia

Phase 1

A Phase 1, open-label, non-comparative, multicenter clinical study to evaluate the safety, tolerability, and pharmacokinetics of ceftolozane/tazobactam (MK-7625A) in pediatric participants with nosocomial pneumonia

CompletedCTIS2022-501110-56-00

Merck Sharp & Dohme LLCNosocomial infection, Pneumonia

Start: 2020-02-26End: 2024-05-30Target: 14Updated: 2024-08-28

Phase 4

Efficacy and safety of 7 versus 14 days of antibiotic treatment for bacteremia produced by Pseudomonas aeruginosa: a multicenter, randomized (SHORTEN-2) clinical trial with a DOOR/RADAR analysis.

Not yet recruitingCTIS2023-508441-41-00

Fundacion Publica Andaluza Para La Gestion De La Investigacion En Salud De SevillaBacteriemia producida por P. aeruginosa.

Target: 306Updated: 2025-07-25